RBL2 and neoplasm: They showed that four tumor-specific mRNA (ALOX5, RBL2, VEGFA, TLK2) present in EVs (defined as present in tumor-derived-, urine- and plasma-EVs, but absent in tumor-adjacent tissue EVs) may be used as RCC biomarkers in the future (Table 1).